TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11003974

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 8769685

Group type: EXPERIMENTAL
Intervention: Pravastatin sodium (10-15 mg/day for an average of 10.2 weeks)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Simvastatin (5-10 mg/day for an average of 13.9 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal subjects (control group)
Number of subjects: 28
Study: 1576841

Group type: EXPERIMENTAL
Intervention: Rehabilitation group (40 sessions over 90 days; specialized equipment)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (11 patients completed the study)
Number of subjects: 25
Study: 4073085

Group type: EXPERIMENTAL
Intervention: Ticarcillin plus clavulanic acid (3 g every four hours)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Clindamycin plus gentamicin (600 mg every six hours plus 3 to 5 mg/kg per day)
Number of subjects: 47
Study: 30178449

Group type: EXPERIMENTAL
Intervention: RIRS (Retrograde Intrarenal Surgery)
Number of subjects: 60

Group type: COMPARATOR
Intervention: mini-Percutaneous Nephrolithotomy (mini-PNL)
Number of subjects: 60
Study: 30415816

Group type: EXPERIMENTAL
Intervention: Ixekizumab (80 mg/2 weeks after 160-mg initial dose)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 26488229

Group type: EXPERIMENTAL
Intervention: 25 mL hybrid palm oil daily for 3 months
Number of subjects: 160

Group type: COMPARATOR
Intervention: 25 mL extra virgin olive oil daily for 3 months
Number of subjects: 160
Study: 24536039

Group type: EXPERIMENTAL
Intervention: Barberry (3 capsules daily for 6 weeks)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo (3 capsules daily for 6 weeks)
Number of subjects: 106
Study: 22821620

Group type: EXPERIMENTAL
Intervention: Epinephrine (10 μg)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Phenylephrine (100 μg)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 93
Study: 20051221

Group type: EXPERIMENTAL
Intervention: Armodafinil (200 mg once daily)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study: 18197497

Group type: COMPARATOR
Intervention: AQP3 in ascending colon (trial group: 0.905, control group: 0.798)
Number of subjects: 66

Group type: COMPARATOR
Intervention: AQP9 in ascending colon (trial group: 0.544, control group: 0.543)
Number of subjects: 66

Group type: COMPARATOR
Intervention: AQP3 in descending colon (trial group: 0.697, control group: 0.701)
Number of subjects: 66

Group type: COMPARATOR
Intervention: AQP9 in descending colon (trial group: 0.575, control group: 0.732)
Number of subjects: 66
Study: 15944884

Group type: EXPERIMENTAL
Intervention: Vestibulopathic subjects
Number of subjects: 35

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 35
Study: 12630074

Group type: EXPERIMENTAL
Intervention: Growth hormone and somatomedins
Number of subjects: 0
Study: 10073832

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 132

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 132
Study: 7491886

Group type: EXPERIMENTAL
Intervention: Low-fat milk (1.4 g Ca/d)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fermented low-fat milk (1.4 g Ca/d)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Soft drink (0.16 g Ca/d)
Number of subjects: 9
Study: 1781044

Group type: EXPERIMENTAL
Intervention: Bone scintigraphy and chest X-ray
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systematic use of bone scintigraphy and chest X-ray
Number of subjects: 0
Study: 30699971

Group type: EXPERIMENTAL
Intervention: 40 g freeze-dried blueberry powder
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo powder
Number of subjects: 63
Study: 27659923

Group type: EXPERIMENTAL
Intervention: Active deep brain stimulation (DBS)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham deep brain stimulation (DBS)
Number of subjects: 25
Study: 26007261

Group type: EXPERIMENTAL
Intervention: Dietary intervention and physical exercise for 12 weeks
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Dietary intervention and physical exercise for 12 weeks (Men)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Dietary intervention and physical exercise for 12 weeks (Women)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Dietary intervention and physical exercise for 12 weeks (35-40 years group)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Dietary intervention and physical exercise for 12 weeks (41-50 years group)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Dietary intervention and physical exercise for 12 weeks (51-63 years group)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Dietary intervention and physical exercise for 12 weeks (BMI 20-25)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Dietary intervention and physical exercise for 12 weeks (BMI >25)
Number of subjects: 33
Study: 23551992

Group type: EXPERIMENTAL
Intervention: Partially hydrolysed guar gum (PHGG), 10 g/d
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (usual diet without PHGG)
Number of subjects: 44
Study: 21342323

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Calcium carbonate (CC)
Number of subjects: 45
Study: 18986749

Group type: EXPERIMENTAL
Intervention: Laserneedle acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Metal needle acupuncture
Number of subjects: 60
Study: 17870123

Group type: EXPERIMENTAL
Intervention: Holding exercises with placebo (group A)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Holding exercises with oxybutynin (group B)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo alone (group C)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Oxybutynin alone (group D)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Alarm treatment (controls, group E)
Number of subjects: 149
Study: 12027843

Group type: EXPERIMENTAL
Intervention: Bain system + ACD with fresh gas flow 4.4‐6.4 l/min
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low flow circle system with 1.5 l/min fresh gas flow
Number of subjects: 16
Study: 10602894

Group type: EXPERIMENTAL
Intervention: Sibling bone marrow transplantation (BMT)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Unrelated donor bone marrow transplantation (BMT)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Disease-free survival (DFS) after sibling BMT
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Disease-free survival (DFS) after URD BMT
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Relapse of CML
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Transplant-related mortality
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Acute graft-versus-host disease (GVHD)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Chronic graft-versus-host disease (GVHD)
Number of subjects: 88
Study: 7589007

Group type: EXPERIMENTAL
Intervention: Fibrin glue (Tissucol, 5 ml of 500 IU thrombin) applied in the area of axillary dissection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no fibrin glue)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fibrin glue (Tissucol, 5 ml of 500 IU thrombin)
Number of subjects: 40
Study: 1939803

Group type: EXPERIMENTAL
Intervention: Composite resin (Herculite XR, Clearfil Ray Posterior, Visiomolar)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Amalgam (Tytin)
Number of subjects: 56
Study: 6792379

Group type: EXPERIMENTAL
Intervention: Seven days of penicillin V potassium (96 patients)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Ten days of penicillin V potassium (95 patients)
Number of subjects: 191
Study: 31120272

Group type: EXPERIMENTAL
Intervention: Monitor and Accept (MA) mindfulness training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monitor Only (MO) mindfulness training
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Treatment (NT) control
Number of subjects: 0
Study: 28232237

Group type: EXPERIMENTAL
Intervention: 40mg of atomoxetine
Number of subjects: 24
Study: 25936475

Group type: EXPERIMENTAL
Intervention: TMAC
Number of subjects: 107

Group type: COMPARATOR
Intervention: MAC
Number of subjects: 107
Study: 21878470

Group type: EXPERIMENTAL
Intervention: Homozygous for the A allele of SNP rs821597
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: DISC1 haplotypes (rs3738401|rs6675281|rs821597|rs821616|rs967244|rs980989)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Haplotype GCGTCG and ACGTTT
Number of subjects: 149
Study: 21502621

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (750 mg/12 h)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg/12 h)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Gatifloxacin (400 mg/24 h)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard antituberculosis treatment alone (Control)
Number of subjects: 61
Study: 18573590

Group type: EXPERIMENTAL
Intervention: EZ‐IO
Number of subjects: 84

Group type: COMPARATOR
Intervention: MAN‐IO
Number of subjects: 84
Study: 17168934

Group type: EXPERIMENTAL
Intervention: Fibre posts (Snowpost) luted with adhesive composite resin cement (Panavia F)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Titanium alloy posts (Parapost) luted with resin cement
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Titanium alloy posts with glass-ionomer cement (Fuji I)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cast post-and-cores luted with resin cement
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cast post-and-cores with glass-ionomer cement
Number of subjects: 50
Study: 15294406

Group type: EXPERIMENTAL
Intervention: Previously prepared saline solutions
Number of subjects: 672

Group type: COMPARATOR
Intervention: Saline solutions exposed for 24, 48, or 72 hours
Number of subjects: 672
Study: 10395855

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccines (ACVs) - full strength, one-third strength, one-tenth strength
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccines (ACVs)
Number of subjects: 481

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 481
Study: 7744190

Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2286480

Group type: EXPERIMENTAL
Intervention: Jogging 2 h/week for 4 months
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study: 7356349

Group type: EXPERIMENTAL
Intervention: Nasal inoculation of 10(8) to 10(9) organisms of Staphylococcus aureus 502A
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sterile broth (control)
Number of subjects: 32
Study: 31120898

Group type: EXPERIMENTAL
Intervention: Augmented motivational interviewing (MI)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Augmented MI
Number of subjects: 175
Study: 29145771

Group type: EXPERIMENTAL
Intervention: Simvastatin/chitosan gel (10 mg/mL) applied three times/day for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simvastatin suspension
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chitosan gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Petroleum gel
Number of subjects: 0
Study: 26703921

Group type: EXPERIMENTAL
Intervention: PA-focused behavioural intervention during PR (3 months) and follow-up support (3 months)
Number of subjects: 32
Study: 24090342

Group type: EXPERIMENTAL
Intervention: 10-meter walk test (10MWT)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: five times sit-to-stand test (FTSST)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: timed up and go test (TUGT)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: cane
Number of subjects: 85

Group type: COMPARATOR
Intervention: walker
Number of subjects: 85

Group type: COMPARATOR
Intervention: crutches
Number of subjects: 85
Study: 23113482

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg intravenous infusion at baseline and 12 months)
Number of subjects: 1199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1199

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 1199
Study: 20166859

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone patch (TTP, 300 microg/day)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study: 17395523

Group type: EXPERIMENTAL
Intervention: 1‐DAY ACUVUE (1DA)
Number of subjects: 282

Group type: COMPARATOR
Intervention: FOCUS DAILIES (FD)
Number of subjects: 282
Study: 16287890

Group type: EXPERIMENTAL
Intervention: Advice to quit
Number of subjects: 4207

Group type: EXPERIMENTAL
Intervention: Willingness to quit inquiry
Number of subjects: 4207

Group type: EXPERIMENTAL
Intervention: Assistance in quitting
Number of subjects: 4207

Group type: EXPERIMENTAL
Intervention: Follow-up offer
Number of subjects: 4207

Group type: EXPERIMENTAL
Intervention: Satisfaction with care
Number of subjects: 4207
Study: 12122534

Group type: EXPERIMENTAL
Intervention: Insufflation of 10 ml/kg air into the stomach
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no air insufflation)
Number of subjects: 78
Study: 10443966

Group type: COMPARATOR
Intervention: n‐3 fatty acid‐deficient, corn oil‐based formula (CO)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Alpha‐linolenic acid-enriched, soy oil-based formula
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Experimental formula enriched with soy and marine oils
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Cheek cell DHA at 36 weeks
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Cheek cell DHA at 57 weeks
Number of subjects: 108
Study: 8703663

Group type: EXPERIMENTAL
Intervention: rilmenidine 1-2 mg day-1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: atenolol 50-100 mg day-1
Number of subjects: 12
Study: 30714794

Group type: EXPERIMENTAL
Intervention: Family-based treatment
Number of subjects: 107
Study: 27540039

Group type: EXPERIMENTAL
Intervention: Oesophageal temperature probe with insulated thermocouples (Group 1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No oesophageal temperature monitoring (Group 2)
Number of subjects: 80
Study: 25545453

Group type: EXPERIMENTAL
Intervention: Almost continuous skin-to-skin contact (SSC)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 37
Study: 23261789

Group type: EXPERIMENTAL
Intervention: Late preterm infants (LPI)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Preterm infants with less negative parenting
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Very preterm infants (VPI)
Number of subjects: 123
Study: 21988726

Group type: EXPERIMENTAL
Intervention: Emphasis Change (EC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Active Control (AC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Passive Control (PC)
Number of subjects: 60
Study: 19954718

Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride (60 mg/day, three times per week) for 1 year
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 47
Study: 17300851

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m2) plus Vinorelbine (25 mg/m2) bi-weekly
Number of subjects: 46
Study: 15167676

Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg until the day before surgery)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no aspirin or discontinued >5 days before surgery)
Number of subjects: 20
Study: 11316974

Group type: EXPERIMENTAL
Intervention: 375 mg/day of orally administered flutamide combined with leuprorelin (initiated on the day of leuprorelin injection)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 375 mg/day of orally administered flutamide combined with leuprorelin (initiated 1 week before leuprorelin injection)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 375 mg/day of orally administered flutamide combined with leuprorelin (initiated 2 weeks before leuprorelin injection)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 375 mg/day of orally administered flutamide combined with leuprorelin (initiated 4 weeks before leuprorelin injection)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Subcutaneous injection of 3.75 mg leuprorelin acetate depot alone
Number of subjects: 26
Study: 9396403

Group type: EXPERIMENTAL
Intervention: GM-CSF during CT only (n = 64)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: GM-CSF during and after CT (n = 66)
Number of subjects: 253

Group type: COMPARATOR
Intervention: No GM-CSF (n = 63)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: GM-CSF after CT only (n = 60)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: GM-CSF during CT
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: GM-CSF after CT
Number of subjects: 253
Study: 7943592

Group type: EXPERIMENTAL
Intervention: Prophylactic octreotide acetate, 150 micrograms to 300 micrograms per day, beginning on day 1
Number of subjects: 28

Group type: COMPARATOR
Intervention: No octreotide treatment (21 patients)
Number of subjects: 28
Study: 3581491

Group type: EXPERIMENTAL
Intervention: 8 mg betahistine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 16 mg betahistine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 32 mg betahistine
Number of subjects: 10
Study: 31789094

Group type: EXPERIMENTAL
Intervention: Physical abuse
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Emotional abuse
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Sexual abuse
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Polyvictimization
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Beliefs supporting aggression
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Well-being and life satisfaction
Number of subjects: 427
Study: 29466079

Group type: EXPERIMENTAL
Intervention: Active recovery (50% maximal aerobic speed)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Passive recovery
Number of subjects: 8
Study: 26916927

Group type: EXPERIMENTAL
Intervention: Standardized physical therapy exercise intervention
Number of subjects: 126

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 126
Study: 24343267

Group type: EXPERIMENTAL
Intervention: Survivorship care plans (SCPs)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control arm (no SCPs)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups (SCP and Control)
Number of subjects: 38
Study: 23054970

Group type: EXPERIMENTAL
Intervention: Pramlintide
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 20428722

Group type: EXPERIMENTAL
Intervention: Exercise program (EP) consisting of aerobic exercise sessions at 50% to 70% of VO2 peak for 30 to 60 minutes, three times a week for three months
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (CG) with no exercise program
Number of subjects: 111
Study: 18201935

Group type: COMPARATOR
Intervention: Nalbuphine (5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine (2 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine (4 mg)
Number of subjects: 0
Study: 15734854

Group type: EXPERIMENTAL
Intervention: DHEA (50 mg daily for 12 weeks)
Number of subjects: 28
Study: 12551868

Group type: EXPERIMENTAL
Intervention: abciximab (24-hour infusion)
Number of subjects: 7800

Group type: EXPERIMENTAL
Intervention: abciximab (48-hour infusion)
Number of subjects: 7800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7800

Group type: EXPERIMENTAL
Intervention: abciximab (48-hour infusion) in patients with negative troponin
Number of subjects: 7800

Group type: EXPERIMENTAL
Intervention: abciximab (48-hour infusion) in patients with elevated C-reactive protein
Number of subjects: 7800
Study: 10383508

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.d. and clarithromycin 500 mg t.d.s. for 14 days (OC14 group)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.d., clarithromycin 500 mg b.d. and amoxycillin 1 g b.d. for 7 days (OCA7 group)
Number of subjects: 145
Study: 8905708

Group type: EXPERIMENTAL
Intervention: Beta-endorphin
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Metenkephalin
Number of subjects: 7
Study: 1676617

Group type: EXPERIMENTAL
Intervention: Acupuncture (needle inserted into Zusanli (St.36) and Sanyinjiao (Sp. 6) points at 12‐24 h after operation)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 6831755

Group type: EXPERIMENTAL
Intervention: Metronidazole alone or in combination with systemic antibiotics
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 33
Study: 30730476

Group type: EXPERIMENTAL
Intervention: Group MP (300 mg pregabalin orally + IV magnesium sulfate 50 mg/kg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group P (300 mg pregabalin orally + placebo IV infusion)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group M (placebo capsule + IV magnesium sulfate 50 mg/kg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Group C (placebo capsule + placebo IV infusion)
Number of subjects: 120
Study: 29988310

Group type: EXPERIMENTAL
Intervention: 12-week strength and conditioning program
Number of subjects: 0

Group type: COMPARATOR
Intervention: 12-week walking program
Number of subjects: 0
Study: 27321385

Group type: EXPERIMENTAL
Intervention: 50 mg vildagliptin twice daily
Number of subjects: 33

Group type: COMPARATOR
Intervention: 100 mg sitagliptin once daily
Number of subjects: 33
Study: 24560392

Group type: EXPERIMENTAL
Intervention: Safety-engineered blood gas syringes
Number of subjects: 550

Group type: COMPARATOR
Intervention: Conventional heparinized syringes
Number of subjects: 550
Study: 22157740

Group type: EXPERIMENTAL
Intervention: 1.5% mepivacaine with epinephrine
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 1.5% mepivacaine mixed with 0.5% bupivacaine
Number of subjects: 93

Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 93
Study: 21054461

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg) with Eurycoma longifolia (200 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Propranolol (80 mg) with placebo (Lactose)
Number of subjects: 14